The pine-tar study: Effect of pine-tar bath on disease severity in moderate-to-severe childhood eczema - A 3 month, randomized, crossover, investigator-blinded clinical trial
Publication in refereed journal

Altmetrics Information
.

Other information
AbstractBackground:
Childhood atopic dermatitis (AD) or eczema is a chronic inflammatory disease associated with pruritus and sleep loss. Pine‐tar is a plant‐derived topical product used by ancient Greeks. A major component of pine‐tar includes polycyclic aromatic hydrocarbons (PAH) which is thought to be anti‐bacterial and anti‐inflammatory. Although the use of pine‐tar is reported as an alternative therapy in some countries, there are no reports of pine‐tar related randomized clinical trials (RCT). Moreover, few standardized bath product clinical trials have so far been performed for AD patients.
Method:
Sample size calculation for RCT was performed in our pilot study in which 34 patients were required per group for a crossover method. A total of 39 patients with physician‐diagnosed AD were recruited from our dermatology outpatient clinic. Within the 3‐month trial, each patient experienced bathing with pine‐tar bath oil or vehicle bath oil for one month in a randomized sequence. A one‐month washout period in between the two treatment periods was used to minimize possible carryover effect. Efficacy and acceptability of the bath products were measured by general patient acceptability of treatment (GAT: very good, good, fair or poor), disease severity (SCORAD: Scoring‐Atopic‐Dermatitis; POEM: Patient‐Oriented‐Eczema‐Measure), quality of life (CDLQI: Children‐Dermatology‐Life –Quality‐Index; PADQLQ: The‐Pediatric‐Allergic‐Disease‐Quality‐of‐Life‐Questionnaire), and other pertinent clinical parameters. Wilcoxon Signed Ranks Test and Mann‐Whitney U Test were used to perform within and between subjects comparison by SPSS. Comparisons were made two‐tailed, p‐values <0.05 were considered statistically significant. This study was approved by the Clinical Research Ethics Committee of our University.
Results:
Statistically significant improvements in the disease severity score SCORAD, patient self‐reported disease severity score POEM, Staphylococcus Aureus colonization status, and log‐transformed blood IgE level were found when patients experienced pine‐tar bathing compared with vehicle bathing. General acceptability and compliance with both products were good, no reported serious adverse events.
Conclusion:
Bathing daily with pine‐tar containing bath product is a recommendable additional practice for AD patients alongside their usual disease management routine.
All Author(s) ListNg W.G.G., Kung J.S.C., Cheng N.S., Hon K.L., Lam H.S., Leung T.F.
Journal nameAllergy
Detailed descriptionSpecial Issue: Abstracts from the European Academy of Allergy and Clinical Immunology Congress, 01–05 June 2019, Lisbon, Portugal
Year2019
Month8
Volume Number74
Issue NumberS106
PublisherWILEY
Pages343 - 343
ISSN0105-4538
eISSN1398-9995
LanguagesEnglish-United States

Last updated on 2020-03-06 at 23:55